nodes	percent_of_prediction	percent_of_DWPC	metapath
Pitavastatin—ABCG2—Teniposide—lymphatic system cancer	0.163	0.184	CbGbCtD
Pitavastatin—ABCG2—Mitoxantrone—lymphatic system cancer	0.114	0.129	CbGbCtD
Pitavastatin—SLCO1B3—Methotrexate—lymphatic system cancer	0.103	0.116	CbGbCtD
Pitavastatin—ABCC2—Vincristine—lymphatic system cancer	0.0868	0.0981	CbGbCtD
Pitavastatin—ABCG2—Vincristine—lymphatic system cancer	0.0785	0.0887	CbGbCtD
Pitavastatin—CYP2C9—Teniposide—lymphatic system cancer	0.0606	0.0685	CbGbCtD
Pitavastatin—SLCO1B1—Methotrexate—lymphatic system cancer	0.0598	0.0676	CbGbCtD
Pitavastatin—ABCC2—Methotrexate—lymphatic system cancer	0.0526	0.0594	CbGbCtD
Pitavastatin—ABCG2—Methotrexate—lymphatic system cancer	0.0475	0.0537	CbGbCtD
Pitavastatin—ABCB1—Mitoxantrone—lymphatic system cancer	0.0411	0.0465	CbGbCtD
Pitavastatin—ALB—Methotrexate—lymphatic system cancer	0.0328	0.037	CbGbCtD
Pitavastatin—ABCB1—Vincristine—lymphatic system cancer	0.0283	0.032	CbGbCtD
Pitavastatin—ABCB1—Methotrexate—lymphatic system cancer	0.0171	0.0194	CbGbCtD
Pitavastatin—Cognitive impairment—Methotrexate—lymphatic system cancer	0.00333	0.0289	CcSEcCtD
Pitavastatin—Interstitial lung disease—Bleomycin—lymphatic system cancer	0.00303	0.0264	CcSEcCtD
Pitavastatin—Interstitial lung disease—Carmustine—lymphatic system cancer	0.00265	0.023	CcSEcCtD
Pitavastatin—Jaundice—Mechlorethamine—lymphatic system cancer	0.00246	0.0214	CcSEcCtD
Pitavastatin—Interstitial lung disease—Mitoxantrone—lymphatic system cancer	0.00246	0.0214	CcSEcCtD
Pitavastatin—Hepatic failure—Fludarabine—lymphatic system cancer	0.00236	0.0206	CcSEcCtD
Pitavastatin—Cognitive disorder—Methotrexate—lymphatic system cancer	0.00201	0.0175	CcSEcCtD
Pitavastatin—Hypoaesthesia—Fludarabine—lymphatic system cancer	0.00146	0.0127	CcSEcCtD
Pitavastatin—Amnesia—Carmustine—lymphatic system cancer	0.00145	0.0126	CcSEcCtD
Pitavastatin—Hepatic failure—Vincristine—lymphatic system cancer	0.00144	0.0126	CcSEcCtD
Pitavastatin—Renal failure acute—Mitoxantrone—lymphatic system cancer	0.00137	0.0119	CcSEcCtD
Pitavastatin—Pain in extremity—Vincristine—lymphatic system cancer	0.0013	0.0113	CcSEcCtD
Pitavastatin—Interstitial lung disease—Methotrexate—lymphatic system cancer	0.00123	0.0107	CcSEcCtD
Pitavastatin—Confusional state—Teniposide—lymphatic system cancer	0.0012	0.0104	CcSEcCtD
Pitavastatin—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00119	0.0103	CcSEcCtD
Pitavastatin—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00119	0.0103	CcSEcCtD
Pitavastatin—Malaise—Fludarabine—lymphatic system cancer	0.00115	0.01	CcSEcCtD
Pitavastatin—Pruritus—Mechlorethamine—lymphatic system cancer	0.00114	0.00992	CcSEcCtD
Pitavastatin—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.0011	0.00959	CcSEcCtD
Pitavastatin—Myalgia—Fludarabine—lymphatic system cancer	0.00109	0.00947	CcSEcCtD
Pitavastatin—Arthralgia—Fludarabine—lymphatic system cancer	0.00109	0.00947	CcSEcCtD
Pitavastatin—Discomfort—Fludarabine—lymphatic system cancer	0.00108	0.00936	CcSEcCtD
Pitavastatin—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00107	0.00933	CcSEcCtD
Pitavastatin—Confusional state—Fludarabine—lymphatic system cancer	0.00105	0.00916	CcSEcCtD
Pitavastatin—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00103	0.00899	CcSEcCtD
Pitavastatin—Rash—Mechlorethamine—lymphatic system cancer	0.00102	0.00884	CcSEcCtD
Pitavastatin—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00102	0.00883	CcSEcCtD
Pitavastatin—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00101	0.00875	CcSEcCtD
Pitavastatin—Feeling abnormal—Teniposide—lymphatic system cancer	0.000979	0.00852	CcSEcCtD
Pitavastatin—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000972	0.00845	CcSEcCtD
Pitavastatin—Nausea—Mechlorethamine—lymphatic system cancer	0.000958	0.00833	CcSEcCtD
Pitavastatin—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000952	0.00828	CcSEcCtD
Pitavastatin—Jaundice—Mitoxantrone—lymphatic system cancer	0.00095	0.00826	CcSEcCtD
Pitavastatin—Urticaria—Teniposide—lymphatic system cancer	0.000944	0.00821	CcSEcCtD
Pitavastatin—Abdominal pain—Teniposide—lymphatic system cancer	0.00094	0.00817	CcSEcCtD
Pitavastatin—Hypoaesthesia—Carmustine—lymphatic system cancer	0.000936	0.00814	CcSEcCtD
Pitavastatin—Dyspepsia—Fludarabine—lymphatic system cancer	0.000919	0.008	CcSEcCtD
Pitavastatin—Fatigue—Fludarabine—lymphatic system cancer	0.000901	0.00783	CcSEcCtD
Pitavastatin—Hypoaesthesia—Vincristine—lymphatic system cancer	0.000894	0.00777	CcSEcCtD
Pitavastatin—Constipation—Fludarabine—lymphatic system cancer	0.000893	0.00777	CcSEcCtD
Pitavastatin—Hypersensitivity—Teniposide—lymphatic system cancer	0.000876	0.00761	CcSEcCtD
Pitavastatin—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000875	0.00761	CcSEcCtD
Pitavastatin—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.000871	0.00757	CcSEcCtD
Pitavastatin—Feeling abnormal—Fludarabine—lymphatic system cancer	0.000861	0.00748	CcSEcCtD
Pitavastatin—Asthenia—Teniposide—lymphatic system cancer	0.000853	0.00741	CcSEcCtD
Pitavastatin—Malaise—Bleomycin—lymphatic system cancer	0.000846	0.00736	CcSEcCtD
Pitavastatin—Pruritus—Teniposide—lymphatic system cancer	0.000841	0.00731	CcSEcCtD
Pitavastatin—Diarrhoea—Teniposide—lymphatic system cancer	0.000813	0.00707	CcSEcCtD
Pitavastatin—Myalgia—Bleomycin—lymphatic system cancer	0.000799	0.00695	CcSEcCtD
Pitavastatin—Back pain—Carmustine—lymphatic system cancer	0.000792	0.00689	CcSEcCtD
Pitavastatin—Discomfort—Bleomycin—lymphatic system cancer	0.000789	0.00686	CcSEcCtD
Pitavastatin—Confusional state—Bleomycin—lymphatic system cancer	0.000772	0.00671	CcSEcCtD
Pitavastatin—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00077	0.00669	CcSEcCtD
Pitavastatin—Back pain—Vincristine—lymphatic system cancer	0.000756	0.00658	CcSEcCtD
Pitavastatin—Asthenia—Fludarabine—lymphatic system cancer	0.000749	0.00652	CcSEcCtD
Pitavastatin—Rash—Teniposide—lymphatic system cancer	0.000749	0.00652	CcSEcCtD
Pitavastatin—Dermatitis—Teniposide—lymphatic system cancer	0.000749	0.00651	CcSEcCtD
Pitavastatin—Headache—Teniposide—lymphatic system cancer	0.000745	0.00647	CcSEcCtD
Pitavastatin—Pruritus—Fludarabine—lymphatic system cancer	0.000739	0.00643	CcSEcCtD
Pitavastatin—Back pain—Mitoxantrone—lymphatic system cancer	0.000737	0.00641	CcSEcCtD
Pitavastatin—Diarrhoea—Fludarabine—lymphatic system cancer	0.000715	0.00621	CcSEcCtD
Pitavastatin—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.000707	0.00614	CcSEcCtD
Pitavastatin—Nausea—Teniposide—lymphatic system cancer	0.000706	0.00614	CcSEcCtD
Pitavastatin—Hepatic failure—Methotrexate—lymphatic system cancer	0.000701	0.0061	CcSEcCtD
Pitavastatin—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000698	0.00607	CcSEcCtD
Pitavastatin—Myalgia—Carmustine—lymphatic system cancer	0.000697	0.00606	CcSEcCtD
Pitavastatin—Malaise—Mitoxantrone—lymphatic system cancer	0.000687	0.00597	CcSEcCtD
Pitavastatin—Renal failure acute—Methotrexate—lymphatic system cancer	0.000682	0.00593	CcSEcCtD
Pitavastatin—Confusional state—Carmustine—lymphatic system cancer	0.000674	0.00586	CcSEcCtD
Pitavastatin—Myalgia—Vincristine—lymphatic system cancer	0.000666	0.00579	CcSEcCtD
Pitavastatin—Rash—Fludarabine—lymphatic system cancer	0.000659	0.00573	CcSEcCtD
Pitavastatin—Dermatitis—Fludarabine—lymphatic system cancer	0.000658	0.00572	CcSEcCtD
Pitavastatin—Headache—Fludarabine—lymphatic system cancer	0.000654	0.00569	CcSEcCtD
Pitavastatin—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000648	0.00564	CcSEcCtD
Pitavastatin—Myalgia—Mitoxantrone—lymphatic system cancer	0.000648	0.00564	CcSEcCtD
Pitavastatin—Discomfort—Mitoxantrone—lymphatic system cancer	0.000641	0.00557	CcSEcCtD
Pitavastatin—Feeling abnormal—Bleomycin—lymphatic system cancer	0.000631	0.00549	CcSEcCtD
Pitavastatin—Confusional state—Mitoxantrone—lymphatic system cancer	0.000627	0.00545	CcSEcCtD
Pitavastatin—Nausea—Fludarabine—lymphatic system cancer	0.00062	0.0054	CcSEcCtD
Pitavastatin—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000609	0.0053	CcSEcCtD
Pitavastatin—Urticaria—Bleomycin—lymphatic system cancer	0.000608	0.00529	CcSEcCtD
Pitavastatin—Insomnia—Carmustine—lymphatic system cancer	0.000605	0.00526	CcSEcCtD
Pitavastatin—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000581	0.00506	CcSEcCtD
Pitavastatin—Insomnia—Vincristine—lymphatic system cancer	0.000577	0.00502	CcSEcCtD
Pitavastatin—Constipation—Carmustine—lymphatic system cancer	0.000572	0.00497	CcSEcCtD
Pitavastatin—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000566	0.00492	CcSEcCtD
Pitavastatin—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000564	0.00491	CcSEcCtD
Pitavastatin—Feeling abnormal—Carmustine—lymphatic system cancer	0.000551	0.00479	CcSEcCtD
Pitavastatin—Fatigue—Vincristine—lymphatic system cancer	0.00055	0.00478	CcSEcCtD
Pitavastatin—Asthenia—Bleomycin—lymphatic system cancer	0.000549	0.00478	CcSEcCtD
Pitavastatin—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000547	0.00476	CcSEcCtD
Pitavastatin—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000547	0.00475	CcSEcCtD
Pitavastatin—Constipation—Vincristine—lymphatic system cancer	0.000546	0.00475	CcSEcCtD
Pitavastatin—Pruritus—Bleomycin—lymphatic system cancer	0.000542	0.00471	CcSEcCtD
Pitavastatin—Fatigue—Mitoxantrone—lymphatic system cancer	0.000536	0.00466	CcSEcCtD
Pitavastatin—Constipation—Mitoxantrone—lymphatic system cancer	0.000531	0.00462	CcSEcCtD
Pitavastatin—Abdominal pain—Carmustine—lymphatic system cancer	0.000528	0.0046	CcSEcCtD
Pitavastatin—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000522	0.00454	CcSEcCtD
Pitavastatin—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000522	0.00454	CcSEcCtD
Pitavastatin—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.000512	0.00445	CcSEcCtD
Pitavastatin—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000508	0.00442	CcSEcCtD
Pitavastatin—Abdominal pain—Vincristine—lymphatic system cancer	0.000504	0.00439	CcSEcCtD
Pitavastatin—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000501	0.00436	CcSEcCtD
Pitavastatin—Urticaria—Mitoxantrone—lymphatic system cancer	0.000494	0.00429	CcSEcCtD
Pitavastatin—Hypersensitivity—Carmustine—lymphatic system cancer	0.000493	0.00428	CcSEcCtD
Pitavastatin—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000491	0.00427	CcSEcCtD
Pitavastatin—Rash—Bleomycin—lymphatic system cancer	0.000483	0.0042	CcSEcCtD
Pitavastatin—Dermatitis—Bleomycin—lymphatic system cancer	0.000482	0.0042	CcSEcCtD
Pitavastatin—Asthenia—Carmustine—lymphatic system cancer	0.00048	0.00417	CcSEcCtD
Pitavastatin—Hypersensitivity—Vincristine—lymphatic system cancer	0.00047	0.00409	CcSEcCtD
Pitavastatin—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000458	0.00398	CcSEcCtD
Pitavastatin—Asthenia—Vincristine—lymphatic system cancer	0.000458	0.00398	CcSEcCtD
Pitavastatin—Diarrhoea—Carmustine—lymphatic system cancer	0.000457	0.00398	CcSEcCtD
Pitavastatin—Nausea—Bleomycin—lymphatic system cancer	0.000455	0.00396	CcSEcCtD
Pitavastatin—Asthenia—Mitoxantrone—lymphatic system cancer	0.000446	0.00388	CcSEcCtD
Pitavastatin—Dizziness—Carmustine—lymphatic system cancer	0.000442	0.00384	CcSEcCtD
Pitavastatin—Diarrhoea—Vincristine—lymphatic system cancer	0.000437	0.0038	CcSEcCtD
Pitavastatin—Hepatitis—Methotrexate—lymphatic system cancer	0.000436	0.00379	CcSEcCtD
Pitavastatin—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000425	0.0037	CcSEcCtD
Pitavastatin—Dizziness—Vincristine—lymphatic system cancer	0.000422	0.00367	CcSEcCtD
Pitavastatin—Rash—Carmustine—lymphatic system cancer	0.000421	0.00367	CcSEcCtD
Pitavastatin—Dermatitis—Carmustine—lymphatic system cancer	0.000421	0.00366	CcSEcCtD
Pitavastatin—Headache—Carmustine—lymphatic system cancer	0.000419	0.00364	CcSEcCtD
Pitavastatin—Rash—Vincristine—lymphatic system cancer	0.000402	0.0035	CcSEcCtD
Pitavastatin—Dermatitis—Vincristine—lymphatic system cancer	0.000402	0.0035	CcSEcCtD
Pitavastatin—Headache—Vincristine—lymphatic system cancer	0.0004	0.00348	CcSEcCtD
Pitavastatin—Nausea—Carmustine—lymphatic system cancer	0.000397	0.00345	CcSEcCtD
Pitavastatin—Rash—Mitoxantrone—lymphatic system cancer	0.000392	0.00341	CcSEcCtD
Pitavastatin—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000391	0.0034	CcSEcCtD
Pitavastatin—Headache—Mitoxantrone—lymphatic system cancer	0.000389	0.00339	CcSEcCtD
Pitavastatin—Nausea—Vincristine—lymphatic system cancer	0.000379	0.0033	CcSEcCtD
Pitavastatin—Nausea—Mitoxantrone—lymphatic system cancer	0.000369	0.00321	CcSEcCtD
Pitavastatin—Back pain—Methotrexate—lymphatic system cancer	0.000367	0.00319	CcSEcCtD
Pitavastatin—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000352	0.00306	CcSEcCtD
Pitavastatin—Malaise—Methotrexate—lymphatic system cancer	0.000342	0.00298	CcSEcCtD
Pitavastatin—Myalgia—Methotrexate—lymphatic system cancer	0.000323	0.00281	CcSEcCtD
Pitavastatin—Arthralgia—Methotrexate—lymphatic system cancer	0.000323	0.00281	CcSEcCtD
Pitavastatin—Discomfort—Methotrexate—lymphatic system cancer	0.000319	0.00278	CcSEcCtD
Pitavastatin—Confusional state—Methotrexate—lymphatic system cancer	0.000312	0.00271	CcSEcCtD
Pitavastatin—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000282	0.00245	CcSEcCtD
Pitavastatin—Insomnia—Methotrexate—lymphatic system cancer	0.00028	0.00244	CcSEcCtD
Pitavastatin—Dyspepsia—Methotrexate—lymphatic system cancer	0.000273	0.00237	CcSEcCtD
Pitavastatin—Fatigue—Methotrexate—lymphatic system cancer	0.000267	0.00232	CcSEcCtD
Pitavastatin—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000255	0.00222	CcSEcCtD
Pitavastatin—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000253	0.0022	CcSEcCtD
Pitavastatin—Urticaria—Methotrexate—lymphatic system cancer	0.000246	0.00214	CcSEcCtD
Pitavastatin—Abdominal pain—Methotrexate—lymphatic system cancer	0.000245	0.00213	CcSEcCtD
Pitavastatin—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000228	0.00198	CcSEcCtD
Pitavastatin—Asthenia—Methotrexate—lymphatic system cancer	0.000222	0.00193	CcSEcCtD
Pitavastatin—Pruritus—Methotrexate—lymphatic system cancer	0.000219	0.0019	CcSEcCtD
Pitavastatin—Diarrhoea—Methotrexate—lymphatic system cancer	0.000212	0.00184	CcSEcCtD
Pitavastatin—Dizziness—Methotrexate—lymphatic system cancer	0.000205	0.00178	CcSEcCtD
Pitavastatin—Rash—Methotrexate—lymphatic system cancer	0.000195	0.0017	CcSEcCtD
Pitavastatin—Dermatitis—Methotrexate—lymphatic system cancer	0.000195	0.0017	CcSEcCtD
Pitavastatin—Headache—Methotrexate—lymphatic system cancer	0.000194	0.00169	CcSEcCtD
Pitavastatin—Nausea—Methotrexate—lymphatic system cancer	0.000184	0.0016	CcSEcCtD
